N OTE 14 – Accumulated other comprehensive income (loss): The components of, and changes within, accumulated other comprehensive income (loss) attributable to Teva are presented in the table below:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Unrealized Gains (Losses) |
|
|
|
|
|
|
|
|
|
Foreign
currency
translation
adjustments |
|
|
Derivative
financial
instruments |
|
|
Actuarial gains
(losses) and
prior service
(costs) credits |
|
|
|
|
|
|
|
|
| Balance as of December 31, 2025, net of taxes |
|
$ |
(2,152 |
) |
|
$ |
(199 |
) |
|
$ |
(39 |
) |
|
$ |
(2,391 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Other comprehensive income (loss) before reclassifications |
|
|
(58 |
) |
|
|
(12 |
) |
|
|
— |
|
|
|
(70 |
) |
| Amounts reclassified to the statements of income |
|
|
— |
|
|
|
10 |
|
|
|
(1 |
) |
|
|
9 |
|
| Release of cumulative translation adjustments |
|
|
(6 |
) |
|
|
— |
|
|
|
— |
|
|
|
(6 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net other comprehensive income (loss) before tax |
|
|
(64 |
) |
|
|
(2 |
) |
|
|
(1 |
) |
|
|
(67 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Corresponding income tax |
|
|
(7 |
) |
|
|
— |
|
|
|
— |
|
|
|
(7 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net other comprehensive income (loss) after tax |
|
|
(71 |
) |
|
|
(2 |
) |
|
|
(1 |
) |
|
|
(74 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Balance as of June 30, 2026, net of taxes |
|
$ |
(2,223 |
) |
|
$ |
(201 |
) |
|
$ |
(40 |
) |
|
$ |
(2,465 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
Net Unrealized Gains (Losses) |
|
|
|
|
|
|
|
| |
|
Foreign
currency
translation
adjustments |
|
|
Derivative
financial
instruments |
|
|
Actuarial gains
(losses) and
prior service
(costs) credits |
|
|
|
|
| |
|
|
|
| Balance as of December 31, 2024, net of taxes |
|
$ |
(2,857 |
) |
|
$ |
(238 |
) |
|
$ |
(52 |
) |
|
$ |
(3,148 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Other comprehensive income (loss) before reclassifications |
|
|
558 |
|
|
|
— |
|
|
|
— |
|
|
|
558 |
|
| Amounts reclassified to the statements of income |
|
|
— |
|
|
|
24 |
|
|
|
(1 |
) |
|
|
23 |
|
| Release of cumulative translation adjustments** |
|
|
181 |
|
|
|
— |
|
|
|
— |
|
|
|
181 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net other comprehensive income (loss) before tax |
|
|
739 |
|
|
|
24 |
|
|
|
(1 |
) |
|
|
762 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Corresponding income tax |
|
|
45 |
|
|
|
— |
|
|
|
— |
|
|
|
45 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net other comprehensive income (loss) after tax* |
|
|
694 |
|
|
|
24 |
|
|
|
(1 |
) |
|
|
717 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Balance as of June 30, 2025, net of taxes |
|
$ |
(2,163 |
) |
|
$ |
(214 |
) |
|
$ |
(53 |
) |
|
$ |
(2,431 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| * |
Amounts do not include a $27 million gain from foreign currency translation adjustments attributable to redeemable and non-redeemable non-controlling interests. |
| ** |
In connection with the sale of Teva’s business venture in Japan. |
|